S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
The Financial Day of Reckoning Has Begun (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
WARNING: Do You Invest with these Banks (Ad)pixel
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
The Financial Day of Reckoning Has Begun (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
WARNING: Do You Invest with these Banks (Ad)pixel
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
The Financial Day of Reckoning Has Begun (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
WARNING: Do You Invest with these Banks (Ad)pixel
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
The Financial Day of Reckoning Has Begun (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
WARNING: Do You Invest with these Banks (Ad)pixel
NASDAQ:TCDA

Tricida - TCDA Stock Forecast, Price & News

$13.60
+0.42 (+3.19%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$12.72
$13.75
50-Day Range
$8.19
$13.60
52-Week Range
$3.80
$13.79
Volume
431,240 shs
Average Volume
438,278 shs
Market Capitalization
$757.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.67

Tricida MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
0.5% Upside
$13.67 Price Target
Short Interest
Bearish
19.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.25
Upright™ Environmental Score
News Sentiment
-0.67mentions of Tricida in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$9.52 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.20) to ($0.94) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

Medical Sector

969th out of 1,124 stocks

Pharmaceutical Preparations Industry

484th out of 555 stocks

TCDA stock logo

About Tricida (NASDAQ:TCDA) Stock

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Analyst Ratings Changes

Separately, The Goldman Sachs Group reduced their price target on shares of Tricida from $22.00 to $16.00 and set a "buy" rating on the stock in a research note on Tuesday, May 24th.

Tricida Stock Down 3.1 %

Shares of TCDA opened at $13.18 on Tuesday. Tricida has a fifty-two week low of $3.80 and a fifty-two week high of $13.79. The firm's 50 day moving average price is $10.20 and its 200 day moving average price is $9.55. The company has a quick ratio of 5.11, a current ratio of 5.11 and a debt-to-equity ratio of 584.92.

Insider Buying and Selling

In other Tricida news, major shareholder Venrock Healthcare Capital Par bought 61,722 shares of the business's stock in a transaction that occurred on Thursday, June 2nd. The shares were purchased at an average cost of $8.78 per share, with a total value of $541,919.16. Following the purchase, the insider now directly owns 5,736,011 shares in the company, valued at $50,362,176.58. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have acquired a total of 999,004 shares of company stock valued at $9,517,079 in the last ninety days. Company insiders own 35.60% of the company's stock.

Receive TCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter.

TCDA Stock News Headlines

Tricida (NASDAQ:TCDA) Hits New 12-Month High at $12.62
Tricida: Q2 Earnings Insights
Tricida: Q2 Earnings Insights - Benzinga
Tricida (TCDA) Scheduled to Post Earnings on Monday
Tricida, Inc. (TCDA)
Tricida - Seeking Alpha
See More Headlines
Receive TCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter.

TCDA Company Calendar

Last Earnings
11/08/2021
Today
8/17/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCDA
Fax
N/A
Employees
57
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.67
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+0.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-176,570,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
35,851,000
Market Cap
$757.10 million
Optionable
Not Optionable
Beta
0.68

Key Executives

  • Dr. Gerrit Klaerner Ph.D. (Age 50)
    Founder, Pres, CEO & Exec. Director
    Comp: $992.55k
  • Mr. Geoffrey M. Parker (Age 57)
    COO, CFO & Exec. VP
    Comp: $656.28k
  • Mr. Robert L. McKague J.D.
    Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer
  • Dr. Dawn Parsell Ph.D. (Age 60)
    Exec. VP of Clinical Devel.
    Comp: $649.17k
  • Ms. Annie Yoshiyama (Age 39)
    VP of Fin. & Chief Accounting Officer
  • Jackie Cossmon
    VP of Investor Relations & Communications
  • Mr. Edward J. Hejlek Esq. (Age 66)
    J.D., Exec. VP of Intellectual Property













TCDA Stock - Frequently Asked Questions

Should I buy or sell Tricida stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TCDA shares.
View TCDA analyst ratings
or view top-rated stocks.

What is Tricida's stock price forecast for 2022?

3 equities research analysts have issued 12-month price targets for Tricida's shares. Their TCDA share price forecasts range from $7.00 to $18.00. On average, they expect the company's share price to reach $13.67 in the next year. This suggests a possible upside of 0.5% from the stock's current price.
View analysts price targets for TCDA
or view top-rated stocks among Wall Street analysts.

How have TCDA shares performed in 2022?

Tricida's stock was trading at $9.56 at the beginning of the year. Since then, TCDA stock has increased by 42.3% and is now trading at $13.60.
View the best growth stocks for 2022 here
.

When is Tricida's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our TCDA earnings forecast
.

How were Tricida's earnings last quarter?

Tricida, Inc. (NASDAQ:TCDA) released its quarterly earnings results on Monday, November, 8th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.09. During the same period in the prior year, the firm earned ($1.55) EPS.

What is Gerrit Klaerner's approval rating as Tricida's CEO?

2 employees have rated Tricida Chief Executive Officer Gerrit Klaerner on Glassdoor.com. Gerrit Klaerner has an approval rating of 100% among the company's employees. This puts Gerrit Klaerner in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Tricida own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Moderna (MRNA) and AT&T (T).

When did Tricida IPO?

(TCDA) raised $175 million in an IPO on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.

What is Tricida's stock symbol?

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Who are Tricida's major shareholders?

Tricida's stock is owned by a number of retail and institutional investors. Top institutional investors include Commodore Capital LP (3.64%), State Street Corp (0.98%), Deutsche Bank AG (0.80%), Northern Trust Corp (0.53%), Millennium Management LLC (0.40%) and Victory Capital Management Inc. (0.35%). Insiders that own company stock include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Kurtis R Kurimsky, Robert J Alpern, Robert Mckague, Sandra I Coufal, Sibling Capital Fund Ii-A LP, Venrock Healthcare Capital Par and Wilhelm Stahl.
View institutional ownership trends
.

How do I buy shares of Tricida?

Shares of TCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tricida's stock price today?

One share of TCDA stock can currently be purchased for approximately $13.60.

How much money does Tricida make?

Tricida (NASDAQ:TCDA) has a market capitalization of $757.10 million. The company earns $-176,570,000.00 in net income (profit) each year or ($2.71) on an earnings per share basis.

How can I contact Tricida?

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.tricida.com. The company can be reached via phone at (415) 429-7800 or via email at ir@tricida.com.

This page (NASDAQ:TCDA) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.